WealthTrust Axiom’s Benitec Biopharma BNTC Stock Holding History

WealthTrust Axiom’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-762	Closed	-$3.09K	–	243
2023 Q2	$3.09K	Hold	762	–	–	﹤0.01%	254
2023 Q1	$2.72K	Hold	762	–	–	﹤0.01%	250
2022 Q4	$2.2K	Hold	762	–	–	﹤0.01%	246
2022 Q3	$4K	Hold	762	–	–	﹤0.01%	244
2022 Q2	$15K	Hold	762	–	–	0.01%	240
2022 Q1	$30K	Hold	762	–	–	0.01%	258
2021 Q4	$33K	Hold	762	–	–	0.01%	256
2021 Q3	$46K	Hold	762	–	–	0.02%	248
2021 Q2	$55K	Hold	762	–	–	0.02%	259
2021 Q1	$66K	Buy	+762	New	+$51.8K	0.02%	240

Other funds holding BNTC

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

WealthTrust Axiom's BNTC Position: Q3 2023 in Review

WealthTrust Axiom sold out of Benitec Biopharma (BNTC) in Q3 2023, closing a stake of 762 shares — an estimated $3.09K sold.

WealthTrust Axiom first reported a position in BNTC in Q1 2021 and held it in 10 quarters. The position peaked at $66K in Q1 2021. 12 funds tracked by Wall St. Rank hold BNTC as of Q3 2023.

WealthTrust Axiom reported no remaining Benitec Biopharma position as of Q3 2023 after selling out during the quarter.
WealthTrust Axiom sold 762 Benitec Biopharma shares in Q3 2023, an estimated $3.09K.
WealthTrust Axiom first reported a position in Benitec Biopharma in Q1 2021 and held it in 10 quarters.
WealthTrust Axiom's Benitec Biopharma position peaked at $66K in Q1 2021.
12 funds tracked by Wall St. Rank held Benitec Biopharma as of Q3 2023.

Based on WealthTrust Axiom's 13F filing for Q3 2023, filed 3 Nov 2023.